,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-01-29 23:00:00,"Global consumer goods retailer, Clorox Company ( CLX ) is scheduled to release its second-quarter 2012 results on Friday, February 03, 2012.",0.03378603607416153,0.006913097575306892,0.9593008160591125,neutral,0.026872938498854637
1,2012-01-29 23:00:00,"The current Zacks Consensus earnings per share ( EPS ) estimate for the second quarter is 69 cents, representing an annualized growth of 1.16%.",0.9450170993804932,0.020040573552250862,0.03494221717119217,positive,0.9249765276908875
2,2012-01-29 23:00:00,"The Zacks Consensus Estimate for full-year 2012 stands at $4.07 per share, reflecting a year-over-year decline of 2.05% and falling within the company's guidance range of $4.00 to $4.10 per share.",0.0187201127409935,0.9723483920097351,0.008931547403335571,negative,-0.9536283016204834
3,2012-01-29 23:00:00,"In the surprises context, Clorox has a history of delivering positive earnings surprises.",0.9256889224052429,0.01637198030948639,0.05793904513120651,positive,0.9093169569969177
4,2012-01-29 23:00:00,We note that the company has outplayed the Zacks Consensus Estimate over the trailing four quarters exhibiting positive surprises with an average of 7.21%.,0.637638509273529,0.22307215631008148,0.13928928971290588,positive,0.4145663380622864
5,2012-01-29 23:00:00,"On November 02, 2011, Clorox posted better-than-expected first-quarter earnings of $1.01 per share, handily beating the Zacks Consensus Estimate of 92 cents per share.",0.9318056106567383,0.049877800047397614,0.018316665664315224,positive,0.8819277882575989
6,2012-01-29 23:00:00,"However, earnings in the quarter were down 7 cents from the year-ago quarter earnings, affected by macroeconomic headwinds and inflationary input cost situation.",0.018272772431373596,0.9718396663665771,0.009887502528727055,negative,-0.9535669088363647
7,2012-01-29 23:00:00,"Clorox's net sales during the quarter inched up 3.0% year over year to $1,305.0 million from $1,266.0 million in the year-ago quarter, primarily driven by product innovation and increased pricing.",0.9600090384483337,0.0218459852039814,0.01814498007297516,positive,0.9381630420684814
8,2012-01-29 23:00:00,"Total revenue beats the Zacks Consensus Estimate of $1,294.0 million.",0.8529847860336304,0.023924414068460464,0.12309081107378006,positive,0.8290603756904602
9,2012-01-29 23:00:00,"Of the 14 analysts following the stock, one analyst revised the second quarter estimate downward in the last 7 days while 2 analysts trimmed estimates in the last 30 days.",0.03504624590277672,0.8998222351074219,0.06513155996799469,negative,-0.8647760152816772
10,2012-01-29 23:00:00,There were no upward revisions in both the periods.,0.03238749876618385,0.02159031108021736,0.9460222125053406,neutral,0.010797187685966492
11,2012-01-29 23:00:00,"For fiscal 2012, 1 out of 15 analysts, slashed estimates in the past 7 days, with no upside to estimates in the same period.",0.01782737486064434,0.9700775742530823,0.01209497544914484,negative,-0.9522501826286316
12,2012-01-29 23:00:00,"In the last 30 days, none of the analysts revised their fiscal 2012 estimates.",0.017552703619003296,0.023349754512310028,0.9590975642204285,neutral,-0.005797050893306732
13,2012-01-29 23:00:00,"For fiscal 2013, 1 out of 14 analysts revised the estimate downward in the last 7 days while 2 analysts pulled down their estimates in the last 30 days.",0.022037072107195854,0.9381390810012817,0.03982384130358696,negative,-0.9161019921302795
14,2012-01-29 23:00:00,There were no upward movements in the last 7 or 30 days.,0.018613383173942566,0.016706444323062897,0.9646801948547363,neutral,0.0019069388508796692
15,2012-01-29 23:00:00,"Despite one downward revision in the 7-day period and 2 estimate cuts in the 30-day period, the estimate for the second quarter remained stable at 69 cents per share.",0.6325610280036926,0.2640198767185211,0.10341906547546387,positive,0.3685411512851715
16,2012-01-29 23:00:00,"With one analyst trimming estimate in the 7-day period, the Zacks Consensus Estimate for fiscal 2012 moved down by a penny to $4.07 per share.",0.01839335635304451,0.9698189496994019,0.011787761934101582,negative,-0.9514256119728088
17,2012-01-29 23:00:00,"However, for the 30-day period, none of the analysts revisited their estimates, thereby keeping the Zacks Consensus Estimate unchanged.",0.06899243593215942,0.21758486330509186,0.7134226560592651,neutral,-0.14859242737293243
18,2012-01-29 23:00:00,"Despite one downward revision in the 7-day period, the Zacks Consensus Estimate for fiscal 2013 remained stable at $4.42 per share.",0.5026084780693054,0.29031145572662354,0.20708003640174866,positive,0.21229702234268188
19,2012-01-29 23:00:00,"However, estimate cuts by 2 analysts in the 30-day period pulled down the Zacks Consensus Estimate by a penny.",0.05071285367012024,0.9346048831939697,0.014682183042168617,negative,-0.8838920593261719
20,2012-01-29 23:00:00,"The Oakland, California-based company possesses a strong portfolio of brands, including Clorox, Glad, Brita, Armor All, Burt's Bees, STP and Kingsford, offering a competitive edge while bolstering its well-established position in the market.",0.9381691813468933,0.015067040920257568,0.04676375165581703,positive,0.9231021404266357
21,2012-01-29 23:00:00,"Further, Clorox is constantly looking for acquisitions and alliances opportunities to boost its market share and product portfolio.",0.9460844397544861,0.015017285943031311,0.03889826685190201,positive,0.931067168712616
22,2012-01-29 23:00:00,"Looking ahead, Clorox targets to earn $4.00 to $4.10 per share of annual earnings based on 1% to 3% growth in sales.",0.7776733636856079,0.013161509297788143,0.2091650515794754,positive,0.7645118832588196
23,2012-01-29 23:00:00,"In an effort to enhance its market share and product portfolio, Clorox is constantly looking for acquisitions and alliances opportunities.",0.912263810634613,0.012604370713233948,0.0751318410038948,positive,0.8996594548225403
24,2012-01-29 23:00:00,"Moreover, Clorox is carefully managing its asset value and focusing on realizing double-digit economic profit growth and free cash flow of 10% of net sales in fiscal 2012.",0.8408615589141846,0.014182171784341335,0.14495627582073212,positive,0.8266794085502625
25,2012-01-29 23:00:00,"However, intense competition from other established players and a highly leveraged balance sheet may undermine the company's future growth prospects.",0.027101119980216026,0.9326894283294678,0.04020947217941284,negative,-0.9055883288383484
26,2012-01-29 23:00:00,"Further, the company's highly leveraged balance sheet with long-term debt of $2,125.0 million and debt-to-capitalization ratio of 104% at the end of fiscal 2011, affect its financial flexibility.",0.13649819791316986,0.2641425132751465,0.5993592143058777,neutral,-0.12764431536197662
27,2012-01-29 23:00:00,"This may, in turn, curtail the company's ability to pursue acquisitions or expand operations organically.",0.024084096774458885,0.9179602265357971,0.05795569345355034,negative,-0.8938761353492737
28,2012-01-29 23:00:00,"Clorox Company, which competes with the likes of Colgate-Palmolive Company ( CL ) and Procter and Gamble Company ( PG ), currently has a Zacks #3 Rank, implying a short-term 'Hold' rating on the stock.",0.2541431784629822,0.06361084431409836,0.6822459697723389,neutral,0.19053232669830322
29,2012-01-29 23:00:00,We have a long-term 'Neutral' recommendation on the stock.,0.03485177457332611,0.0389416478574276,0.926206648349762,neutral,-0.004089873284101486
30,2012-01-29 23:00:00,To read this article on Zacks.com click here.,0.01796119473874569,0.0192450862377882,0.9627937078475952,neutral,-0.001283891499042511
31,2012-01-29 23:00:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
